Lantern Pharma Inc. (LTRN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Lantern Pharma Inc. (LTRN) trades at $3.25 with AI Score 46/100 (Weak). Lantern Pharma Inc. is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to accelerate drug development. Market cap: 36349375, Sector: Healthcare.
Last analyzed: Feb 9, 2026Lantern Pharma Inc. (LTRN) Healthcare & Pipeline Overview
Lantern Pharma: Revolutionizing drug development with AI-powered RADR platform, targeting unmet needs in oncology with a pipeline led by LP-100 in Phase II trials for metastatic prostate cancer, offering a data-driven approach to precision medicine and improved patient outcomes.
Investment Thesis
Lantern Pharma presents a notable research candidate due to its innovative AI-driven approach to drug development and a promising pipeline of oncology therapeutics. The RADR platform provides a significant competitive advantage by accelerating drug discovery and improving clinical trial outcomes. The Phase II clinical trials for LP-100 targeting metastatic, castration-resistant prostate cancer represent a near-term value driver. Positive clinical data and potential partnerships could significantly increase the company's valuation. The company's market capitalization of $0.03 billion, coupled with its potential to disrupt the traditional drug development process, makes it an attractive investment for those seeking exposure to innovative biotechnology companies. The development of LP-300 and LP-184 offer additional upside potential.
Based on FMP financials and quantitative analysis
Key Highlights
- LP-100 is in Phase II clinical trials for metastatic, castration-resistant prostate cancer, representing a key value driver.
- The RADR AI platform streamlines drug development, potentially reducing costs and accelerating timelines.
- Developing LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma expands the target market.
- LP-184, a preclinical development drug candidate, targets cancer cells with specific biomarkers or DNA repair pathway mutations.
- The company operates an ADC program, an antibody drug conjugate therapeutic approach for cancer treatment, diversifying its therapeutic pipeline.
Competitors & Peers
Strengths
- Proprietary AI platform (RADR) for drug discovery.
- Pipeline of oncology therapeutics targeting unmet needs.
- Experienced management team with expertise in AI and drug development.
- Focus on personalized cancer treatments.
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on successful clinical trial outcomes.
- High risk associated with drug development.
- Small number of employees.
Catalysts
- Upcoming: Data readout from Phase II clinical trials of LP-100 in metastatic, castration-resistant prostate cancer.
- Upcoming: Announcement of new partnerships or collaborations.
- Ongoing: Advancement of LP-300 through clinical development.
- Ongoing: Progress of LP-184 through preclinical studies.
- Ongoing: Expansion of the RADR AI platform capabilities.
Risks
- Potential: Failure to obtain positive clinical trial results.
- Potential: Inability to secure funding for drug development.
- Potential: Competition from other biotechnology and pharmaceutical companies.
- Ongoing: Regulatory hurdles and delays in drug approval processes.
- Ongoing: Dependence on key personnel and intellectual property.
Growth Opportunities
- Advancement of LP-100 through Phase II clinical trials: Successful completion of Phase II trials for LP-100 in metastatic, castration-resistant prostate cancer could lead to significant market opportunities. The prostate cancer treatment market is substantial, and positive data could attract partnerships or acquisition interest. This advancement is expected within the next 1-2 years.
- Expansion of the RADR AI platform: The RADR platform can be expanded to identify and develop new drug candidates across various cancer types. This expansion could lead to a broader pipeline and increased revenue streams. The market for AI-driven drug discovery is growing rapidly, creating significant opportunities for Lantern Pharma.
- Development of LP-300 for non-small cell lung cancer: LP-300 targets a specific subset of non-small cell lung cancer patients (non or never-smokers), representing a niche market with unmet needs. Successful development and commercialization of LP-300 could generate substantial revenue.
- Progressing LP-184 through preclinical development: LP-184's unique mechanism of action, targeting DNA damage in cancer cells, offers potential for treating cancers with specific biomarkers or DNA repair mutations. Advancing LP-184 through preclinical studies and into clinical trials could unlock significant value.
- Strategic partnerships and collaborations: Forming partnerships with larger pharmaceutical companies or research institutions can provide access to funding, expertise, and resources, accelerating the development and commercialization of Lantern Pharma's drug candidates. These partnerships could also validate the RADR platform and attract further investment.
Opportunities
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of the RADR platform to new therapeutic areas.
- Positive clinical trial data leading to regulatory approvals.
- Growing market for AI-driven drug discovery.
Threats
- Competition from larger pharmaceutical companies.
- Failure to obtain regulatory approvals.
- Unfavorable clinical trial results.
- Changes in the regulatory landscape.
Competitive Advantages
- Proprietary AI platform (RADR) provides a competitive advantage in drug discovery.
- Focus on personalized cancer treatments targeting specific genetic profiles.
- Pipeline of novel drug candidates with unique mechanisms of action.
- Expertise in AI, genomics, and drug development.
About LTRN
Founded in 2013 and headquartered in Dallas, Texas, Lantern Pharma Inc. is a clinical-stage biotechnology company focused on transforming cancer treatment through the application of artificial intelligence (AI), machine learning (ML), and genomic data. The company's core mission is to streamline the drug development process, reduce costs, and improve the probability of success in bringing novel therapies to market. Lantern Pharma's proprietary AI platform, RADR, analyzes vast amounts of molecular and clinical data to identify potential drug candidates and predict patient response. Their lead drug candidate, LP-100, is currently in Phase II clinical trials for the treatment of metastatic, castration-resistant prostate cancer. The company is also developing LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. Additionally, their preclinical development drug candidate, LP-184, is an alkylating agent designed to damage DNA in cancer cells that overexpress certain biomarkers or harbor mutations in DNA repair pathways. Lantern Pharma is also advancing an antibody-drug conjugate (ADC) program, further expanding its therapeutic pipeline. By integrating AI and genomic insights, Lantern Pharma aims to deliver personalized cancer treatments with enhanced efficacy and reduced side effects.
What They Do
- Develop AI-driven drug discovery platform (RADR).
- Identify and develop novel cancer therapeutics.
- Conduct clinical trials for lead drug candidates.
- Target specific cancer subtypes with personalized treatments.
- Utilize genomic data and machine learning to improve drug efficacy.
- Advance preclinical drug candidates through research and development.
- Pursue strategic partnerships to expand pipeline and market reach.
Business Model
- Develop and out-license drug candidates to larger pharmaceutical companies.
- Generate revenue through research grants and collaborations.
- Potentially commercialize drugs directly upon regulatory approval.
- Utilize AI platform (RADR) to reduce drug development costs and timelines.
Industry Context
The biotechnology industry is characterized by high risk and high reward, with companies like Lantern Pharma focusing on innovative approaches to drug development. The application of AI and machine learning in drug discovery is a growing trend, driven by the need to reduce development costs and improve success rates. The competitive landscape includes companies such as ANVS, ATNM, BCAB, CALC, and ELUT, but Lantern Pharma differentiates itself through its RADR AI platform. The oncology market is a significant area of focus, with a global market size expected to reach hundreds of billions of dollars in the coming years.
Key Customers
- Patients with cancer.
- Pharmaceutical companies seeking novel drug candidates.
- Research institutions interested in AI-driven drug discovery.
- Investors seeking exposure to innovative biotechnology companies.
Financials
Chart & Info
Lantern Pharma Inc. (LTRN) stock price: $3.25 (+0.14, +4.50%)
Latest News
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Mar 31, 2026
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Mar 31, 2026
-
Earnings Scheduled For March 30, 2026
benzinga · Mar 30, 2026
-
Why PMGC Holdings Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
benzinga · Mar 30, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LTRN.
Price Targets
Consensus target: $20.00
MoonshotScore
What does this score mean?
The MoonshotScore rates LTRN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Earnings Scheduled For March 30, 2026
Why PMGC Holdings Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
Common Questions About LTRN
What does Lantern Pharma Inc. do?
Lantern Pharma Inc. is a clinical-stage biotechnology company that leverages its proprietary AI platform, RADR, to accelerate the development of novel cancer therapeutics. The company focuses on identifying and developing personalized treatments for specific cancer subtypes, utilizing genomic data and machine learning to improve drug efficacy and reduce development costs. Their lead drug candidate, LP-100, is currently in Phase II clinical trials for metastatic, castration-resistant prostate cancer, with other drug candidates in preclinical and clinical development. Lantern Pharma aims to transform cancer treatment through its innovative AI-driven approach.
Is LTRN stock worth researching?
LTRN stock represents a high-risk, high-reward investment opportunity. The company's innovative AI-driven approach to drug discovery and promising pipeline of oncology therapeutics offer significant growth potential. However, investors should be aware of the risks associated with clinical-stage biotechnology companies, including the potential for clinical trial failures and regulatory hurdles. With a market capitalization of $0.03 billion and a P/E ratio of -1.51, LTRN's valuation is sensitive to positive clinical data and strategic partnerships. A balanced approach considering both the potential upside and inherent risks is crucial before investing.
What are the main risks for LTRN?
The main risks for Lantern Pharma include the potential for clinical trial failures, which could significantly impact the company's valuation and future prospects. Securing adequate funding for drug development is also a critical risk, as the company relies on capital markets and partnerships to finance its operations. Competition from larger pharmaceutical companies and regulatory hurdles in the drug approval process pose additional challenges. Dependence on key personnel and the protection of intellectual property are also important risk factors to consider. These risks are inherent in the biotechnology industry and require careful monitoring.
What are the key factors to evaluate for LTRN?
Lantern Pharma Inc. (LTRN) currently holds an AI score of 46/100, indicating low score. Analysts target $20.00 (+515% from $3.25). Key strength: Proprietary AI platform (RADR) for drug discovery.. Primary risk to monitor: Potential: Failure to obtain positive clinical trial results.. This is not financial advice.
How frequently does LTRN data refresh on this page?
LTRN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven LTRN's recent stock price performance?
Recent price movement in Lantern Pharma Inc. (LTRN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $20.00 implies 515% upside from here. Notable catalyst: Proprietary AI platform (RADR) for drug discovery.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider LTRN overvalued or undervalued right now?
Determining whether Lantern Pharma Inc. (LTRN) is overvalued or undervalued requires examining multiple metrics. Analysts target $20.00 (+515% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying LTRN?
Before investing in Lantern Pharma Inc. (LTRN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment in biotechnology companies is inherently risky and speculative.